Biomarker profiling for cancer diagnosis, prognosis and therapeutic management

National Medical Journal of India

Volumn 18, Issue 6, 2005, Pages 304-312

  Mitra, Anirban P ^a   Lin, Henry ^a   Cote, Richard J ^a   Datar, Ram H ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; NITRIC OXIDE SYNTHASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C MYB; PROTEIN KINASE B; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR E2F; TRASTUZUMAB; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; COLORECTAL CANCER; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DNA MICROARRAY; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TRANSFER; HEALTH CARE COST; HUMAN; LUNG CANCER; LYMPHADENECTOMY; NEUROBLASTOMA; OVARY TUMOR; PREDICTION; PREVALENCE; PROGNOSIS; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

GENE EXPRESSION PROFILING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 32544433464     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Weidner N. Tumor angiogenesis: Review of current applications in tumor prognostication. Semin Diagn Pathol 1993;10:302-13.
2. Brawer MK, Lange PH. Prostate-specific antigen in management of prostatic carcinoma. Urology 1989;33:11-16.
3. Yachnin S. The clinical significance of human alpha-fetoprotein. Ann Clin Lab Sci 1978;8:84-90.
4. Sugarbaker PH. Role of carcinoembryonic antigen assay in the management of cancer. Adv Immun Cancer Ther 1985;1:167-93.
5. Funk JO. Cancer cell cycle control. Anticancer Res 1999;19:4772-80.
6. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
7. Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene 1991;6:2055-65.
8. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990;10:6565-77.
9. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331: 1259-64.
10. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
11. Li D, Tian Y, Ma Y, Benjamin T. p150 (Sal2) is a p53-independent regulator of p21 (WAF1/CIP). Mol Cell Biol 2004;24:3885-93.
12. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991;65:1053-61.
13. Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997;15:3301-12.
14. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
15. Cory S, Huang DC, Adams JM. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
16. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
17. Ahmed A, Dunk C, Kniss D, Wilkes M. Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab Invest 1997;76:779-91.
18. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996;16: 360-6.
19. George B, Cote RJ, Datar RH. Nucleic acids in disease prognosis. Natl Med J India 2001;14:163-7.
20. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 2003;8:307-25.
21. Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR, et al. HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 2004;90:163-70.
22. Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor. Eur J Obstet Gynecol Reprod Biol 1997; 71:173-9.
23. Ross JS, Gray GS. Targeted therapy for cancer: The HER-2/neu and Herceptin story. Clin Leadersh Manag Rev 2003;17:333-40.
24. Datar RH. Nucleic acids in disease: Information launch-pad. Natl Med J India 2000; 13:255-2.
25. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
26. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, et al. Oligodendroglial tumors: Refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004;14:121-30.
27. International Agency for Research on Cancer. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancerbase No.5 version 2.0. Lyon: IARC Press, 2004. www-dep.iarc.fr (accessed on 4 Jan 2006)
28. World Health Organization. The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol 1982;77:123-36.
29. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: The Japanese experience. Ann Thorac Surg 2001;71:1759-64.
30. Kwiatkowski DJ, Harpole DH Jr, Godleski J, Herndon JE 2nd, Shieh DB, Richards W, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications. J Clin Oncol 1998;16:2468-77.
31. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828-31.
32. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
33. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993;85:2018-23.
34. Fujino M, Dosaka-Akita H, Harada M, Hiroumi H, Kinoshita I, Akie K, et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer 1995;76:2457-63.
35. Xu HJ, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 1994;86:695-9.
36. Dosaka-Akita H, Hu SX, Fujino M, Harada M, Kinoshita I, Xu HJ, et al. Altered retinoblastoma protein expression in nonsmall cell lung cancer: Its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 1997;79: 1329-37.
37. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, et al. Bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell long cancer. Br J Cancer 1995;71:1003-7.
38. Choi J, Choi K, Benveniste EN, Hong YS, Lee JH, Kim J, et al. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res 2005;65:5554-60.
39. Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in Stage I-III lung carcinoma. Cancer Lett 2005 June 24 (Epub ahead of print)
40. Yamaguchi M, Sugio K, Ondo K, Yano T, Sugimachi K. Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 2002;36:143-50.
41. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998;115:1007-14.
42. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer 2001;33:125-32.
43. Harris Y, Marrow M, Norton L. Malignant tumor of the breast. In: DeVita VT, Hellman S, Rosenberg SA (eds). Principles and practice of oncology. Vol. 1. Fifth edition. Philadelphia:Lippincott-Raven Publishers; 1997:1557-616.
44. Ravaioli A, Bagli L, Zucchini A, Monti F. Prognosis and prediction of response in breast cancer: The current role of the main biological markers. Cell Prolif 1998;31:113-26.
45. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-5.
46. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 2004;10:6215-21.
47. Peters MG, Vidal Mdel C, Gimenez L, Mauro L, Armanasco E, Cresta C, et al. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. Oncol Rep 2004;12:1143-50.
48. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 2003;5:R242-9.
49. Ceccarelli C, Santini D, Chieco P, Taffurelli M, Gamberini M, Pileri SA, et al. Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile. J Clin Pathol 1998;51:818-24.
50. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 2004;198:83-90.
51. Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, et al. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer 2003;98:2554-9.
52. Bukholm IR, Bukholm G, Nesland JM. Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas. Apmis 2002;110:214-20.
53. Fontana A, Filleur S, Guglielmi J, Frappart L, Bruno-Bossio G, Boissier S, et al. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer 2005;116:686-91.
54. Rice AJ, Steward MA, Quinn CM. Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast. J Clin Pathol 2002; 55:921-5.
55. Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 2005;92:553-61.
56. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005;89:215-20.
57. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett 2005;217:237-42.
58. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10:7621-8.
59. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: A review. Am J Gastroenterol 2005;100:1393-403.
60. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23:7518-28.
61. Prall F, Ostwald C, Nizze H, Barten M. Expression profiling of colorectal carcinomas using tissue microarrays: Cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis. Appl Immunohistochem Mol Morphol 2004;12:111-21.
62. Schwandner O, Bruch HP, Broll R. Prognostic significance of p21 and p27 protein, apoptosis, clinical and histologic factors in rectal cancer without lymph node metastases. Eur Surg Res 2002;34:389-96.
63. Cui X, Shirai Y, Wakai T, Yokoyama N, Hirano S, Hatakeyama K. Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 2004;35: 1189-95.
64. Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Scholefield JH, et al. Evidence that the p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients. World J Surg Oncol 2005;3:47.
65. Maeda K, Nishiguchi Y, Kang SM, Yashiro M, Onoda N, Sawada T, et al. Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep 2001;8:763-6.
66. Miyanaga K, Kato Y, Nakamura T, Matsumura M, Amaya H, Horiuchi T, et al. Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res 2002;22:3941-8.
67. Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998;78:1379-84.
68. Maeda K, Nishiguchi Y, Yashiro M, Yamada S, Onoda N, Sawada T, et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000;5:373-8.
69. Kaio E, Tanaka S, Oka S, Hiyama T, Kitadai Y, Haruma K, et al. Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma. Int J Oncol 2003;23:901-11.
70. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004;10:8229-34.
71. Moran A, Iniesta P, Garcia-Aranda C, De Juan C, Diaz-Lopez A, Sanchez-Pernaute A, et al. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep 2005;13:115-20.
72. Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F, et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 2004;10:5572-9.
73. Kouraklis G, Misiakos EP. Hereditary nonpolyposis colorectal cancer (Lynch syndrome): Criteria for identification and management. Dig Dis Sci 2005;50: 336-44.
74. Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 2005;4:255-65.
75. Maruniak NA, Takezawa K, Murphy WM. Accurate pathological staging of urothelial neoplasms requires better cystoscopic sampling. J Urol 2002;167:2404-7.
76. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-9.
77. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003;61:1140-5.
78. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995;71:831-5.
79. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4.
80. Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK, et al. Hyperphosphorylation of pRb: A mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004;203:762-70.
81. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007-13.
82. Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998;16:933-43.
83. Hussain SA, Ganesan R, Hiller L, Cooke PW, Murray P, Young LS, et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep 2003;10:571-6.
84. Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, et al. Prognostic factors in transitional cell cancer of the bladder: An emerging role for Bcl-2 and p53. Radiother Oncol 2001;61:169-75.
85. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, et al. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219-27.
86. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995;55: 510-13.
87. Papathoma AS, Petraki C, Grigorakis A, Papakonstantinou H, Karavana V, Stefanakis S, et al. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 2000;20:2009-13.
88. Mocellin S, Wang E, Panelli M, Pilati P, Marincola FM. DNA array-based gene profiling in tumor immunology. Clin Cancer Res 2004;10:4597-606.
89. Bucca G, Carruba G, Saetta A, Muti P, Castagnetta L, Smith CP. Gene expression profiling of human cancers. Ann N Y Acad Sci 2004;1028:28-37.
90. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
91. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz P, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
92. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415: 530-6.
93. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-80.
94. Apostolakos MJ, Schuermann WH, Frampton MW, Utell MJ, Willey JC. Measurement of gene expression by multiplex competitive polymerase chain reaction. Anal Biochem 1993;213:277-84.
95. Willey JC, Crawford EL, Jackson CM, Weaver DA, Hoban JC, Khuder SA, et al. Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am J Respir Cell Mol Biol 1998;19:6-17.
96. Shen Y, Smith RD. Proteomics based on high-efficiency capillary separations. Electrophoresis 2002;23:3106-24.
97. White CN, Chan DW, Zhang Z. Bioinformatics strategies for proteomic profiling. Clin Biochem 2004;37:636-41.
98. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422: 198-207.
99. Lee KH. Proteomics: A technology-driven and technology-limited discovery science. Trends Biotechnol 2001;19:217-22.
100. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61:6029-33.
101. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359: 572-7.
102. O'Shannessy DJ, Brigham-Burke M, Peck K. Immobilization chemistries suitable for use in the BIAcore surface plasmon resonance detector. Anal Biochem 1992;205:132-6.
103. Fagerstam LG, Frostell-Karlsson A, Karlsson R, Persson B, Ronnberg I. Biospecific interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis. J Chromatogr 1992;597:397-410.
104. Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001;61:6851-9.
105. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-7.
106. Mitra AP, Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU Int 2005;96:7-12.